Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1301-1320 of 3,900 trials

Solid Tumors: [177Lu]Lu-AKIR001 Treatment

We are testing a new treatment for adults with solid tumors that express CD44v6. The study aims to evaluate its safety and how well it works against these tumors.

Advanced Solid TumorsSafety phase (I)Oncology

Long-Term Follow-Up of CAR T-Cell Therapy Patients

We are studying the long-term effects and safety of CAR T-cell therapy in patients who have received this treatment. This includes monitoring for delayed side effects and the persistence of modified T-cells in the blood.

Multiple MyelomaB-cell LymphomaB-cell Type Acute Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Intrathecal Baclofen for Spinal Cord Injury: Safety Study

We are investigating whether intrathecal baclofen is safe for spinal cord injury patients, particularly regarding lung function and sleep disorders. The study also looks at its potential to reduce muscle stiffness and improve daily activities.

Spinal Cord Injury>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyPulmonology

Thrombosis Prevention in Surgery: Apixaban Study

We are studying whether the medication apixaban can help prevent blood clots in patients undergoing general abdominal, gynecologic, and urologic surgeries. This trial compares its effects to not using any anticoagulants during surgery.

Venous Thromboembolism>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal MedicineOrthopedics and TraumatologyUrology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Crohn's Disease: Vedolizumab vs. Adalimumab Dose Increase

We are studying whether Vedolizumab is more effective than increasing the dose of Adalimumab for Crohn's disease patients who are not responding well to their current treatment. This trial will help us understand which strategy leads to better remission and fewer side effects.

Crohn's Disease3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Uveal Melanoma: New Liver Treatment with Ipilimumab and Nivolumab

We are testing a new liver treatment combined with two immunotherapy drugs for patients with uveal melanoma that has spread to the liver. This study aims to see if the new approach improves survival without disease progression compared to standard treatment.

Uveal Melanoma with Liver Metastases3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Heart Failure: Balcinrenone/Dapagliflozin Study

We are evaluating a new treatment combining balcinrenone and dapagliflozin for patients with heart failure and kidney problems. The study aims to see if this combination reduces heart-related events and improves health compared to standard treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyNephrology

Fragile X Syndrome: Long-Term Study of ZYN002 Gel

We are examining the long-term safety and tolerability of a gel medication for children and young adults with Fragile X Syndrome. This study includes participants who have previously used the medication and are continuing to see if it helps manage their symptoms.

Fragile X Syndrome≤3 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurologyPediatrics

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Advanced Solid Tumors: RMC-6291 and RMC-6236 Combination Study

We are examining how well different doses of RMC-6291 and RMC-6236 are tolerated by people with advanced KRASG12C-mutated solid tumors. This study aims to gather important safety information about this treatment combination.

Non-Small Cell Lung CancerPancreatic AdenocarcinomaColorectal Cancer>2 yearsSafety phase (I)Oncology

Kidney Transplant Rejection: Efgartigimod PH20 SC

We are studying a new treatment for kidney transplant recipients facing antibody-mediated rejection. The trial aims to evaluate the safety and how well this medication works compared to a placebo.

Antibody-Mediated Rejection1-2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementInternal MedicineNephrology

Roxadustat: Impact on Heart and Metabolism

We are investigating how roxadustat influences glucose and fat metabolism and heart function in participants. This study may help us understand its potential benefits for cardiovascular health.

Risk Factors for Cardiovascular DiseaseMetabolic Syndrome1-2 yearsMonitoring phase (IV)Standard MedicinesCardiologyEndocrinologyInternal Medicine

Chronic Inflammatory and Fibrotic Diseases: 68Gallium-FAPI PET/CT Imaging Study

We are exploring how a new imaging method can help assess chronic inflammatory and fibrotic diseases. This study aims to understand the relationship between imaging results and disease severity, quality of life, and other health indicators.

Inflammatory Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational Medicines